AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
The liver fibrosis market is driven by innovation from key players such as Akero, Sagimet, Inventiva, Novo Nordisk, Viking, Boston Pharma, Aligos, Boehringer Ingelheim, and 89bio. The market is expected to grow due to the rising prevalence of chronic conditions like hepatitis, obesity, and alcohol use, which can advance to cirrhosis or liver cancer if untreated. Advances in antifibrotic therapies and non-invasive diagnostics are enhancing disease management, while liver transplantation remains a definitive cure. Challenges include limited approved therapies and high treatment costs.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet